Institute of Chemical Biology, Shenzhen Bay Laboratories, 518132 Shenzhen, Guangdong, China.
New Drug R&D Center, North China Pharmaceutical Corporation, 050015 Shijiazhuang, Hebei, China.
Front Biosci (Landmark Ed). 2021 Oct 30;26(10):789-798. doi: 10.52586/4988.
: The coronavirus disease 2019 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected more than 210 million individuals globally and resulted in over 4 million deaths since the first report in December 2019. The early use of traditional Chinese medicine (TCM) for light and ordinary patients, can rapidly improve symptoms, shorten hospitalization days and reduce severe cases transformed from light and normal. Many TCM formulas and products have a wide application in treating infectious and non-infectious diseases. Sieb. et Zucc. (), is an important Traditional Chinese Medicine with actions of clearing away heat and eliminating dampness, draining the gallbladder to relieve jaundice, removing blood stasis to alleviate pain, resolving phlegm and arrest cough. In the search for anti-SARS-CoV-2, was recommended as as a therapeutic drug of COVID-19 pneumonia.In this study, we aimed to identifies is the potential broad-spectrum inhibitor for the treatment of coronaviruses infections. : In the present study , we infected human malignant embryonal rhabdomyoma (RD) cells with the OC43 strain of the coronavirus, which represent an alternative model for SARS-CoV-2 and then employed the cell viability assay kit for the antiviral activity. We combined computer aided virtual screening to predicte the binding site and employed Surface plasmon resonance analysis (SPR) to comfirm the interaction between drugs and coronavirus. We employed fluorescence resonance energy transfer technology to identify drug's inhibition in the proteolytic activity of 3CLpro and Plpro. : Based on our results, polydatin and resveratrol derived from P. cuspidatum significantly suppressed HCoV-OC43 replication. 50% inhibitory concentration (IC) values of polydatin inhibited SARS-CoV-2 Mpro and Plpro, MERS Mpro and Plpro were 18.66, 125, 14.6 and 25.42 μm, respectively. IC values of resveratrol inhibited SARS-CoV-2 Mpro and Plpro, MERS Mpro and Plpro were 29.81 ,60.86, 16.35 and19.04 μM, respectively. Finally, SPR assay confirmed that polydatin and resveratrol had high affinity to SARS-CoV-2, SARS-CoV 3Clpro, MERS-CoV 3Clpro and PLpro protein. : we identified the antiviral activity of flavonoids polydatin and resveratrol on RD cells. Polydatin and resveratrol were found to be specific and selective inhibitors for SARS-CoV-2, 3CLpro and PLpro, viral cysteine proteases. In summary, this study identifies as the potential broad-spectrum inhibitor for the treatment of coronaviruses infections.
新型冠状病毒病 2019 大流行是由严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)引起的,自 2019 年 12 月首次报告以来,已在全球感染超过 2.1 亿人,并导致超过 400 万人死亡。早期使用中药(TCM)治疗轻症和普通患者,可以迅速改善症状,缩短住院天数,并减少轻症和普通患者转为重症的情况。许多中药方剂和产品在治疗感染性和非感染性疾病方面有广泛的应用。白头翁(Sieb. et Zucc.)是一种重要的中药,具有清热利湿、泻胆退黄、活血化瘀、化痰止咳的作用。在寻找抗 SARS-CoV-2 的药物时,白头翁被推荐为 COVID-19 肺炎的治疗药物。在本研究中,我们旨在确定白头翁是否是治疗冠状病毒感染的潜在广谱抑制剂。
在本研究中,我们用冠状病毒 OC43 株感染人恶性胚胎横纹肌瘤(RD)细胞,这是 SARS-CoV-2 的替代模型,然后采用细胞活力测定试剂盒检测抗病毒活性。我们结合计算机辅助虚拟筛选预测结合位点,并采用表面等离子体共振分析(SPR)确认药物与冠状病毒的相互作用。我们采用荧光共振能量转移技术鉴定药物对 3CLpro 和 Plpro 蛋白水解活性的抑制作用。
基于我们的结果,来源于白头翁的白藜芦醇和虎杖苷显著抑制了 HCoV-OC43 的复制。白藜芦醇和虎杖苷对 SARS-CoV-2 Mpro 和 Plpro 的 50%抑制浓度(IC)值分别为 18.66、125、14.6 和 25.42 μm;对 MERS Mpro 和 Plpro 的 IC 值分别为 29.81、60.86、16.35 和 19.04 μM。最后,SPR 试验证实白藜芦醇和虎杖苷对 SARS-CoV-2、SARS-CoV 3CLpro、MERS-CoV 3CLpro 和 PLpro 蛋白具有高亲和力。
我们鉴定了白头翁中的黄酮类化合物白藜芦醇和虎杖苷对 RD 细胞的抗病毒活性。白藜芦醇和虎杖苷被发现是 SARS-CoV-2、3CLpro 和 PLpro,即病毒半胱氨酸蛋白酶的特异性和选择性抑制剂。综上所述,本研究确定白头翁是治疗冠状病毒感染的潜在广谱抑制剂。